What's New in the Evolving Treatment Paradigm in Moderate-to-Severe Rheumatoid Arthritis (RA)
 

A continuing medical education activity sponsored by NAMCP and AAMCN.

This activity is an archive from the live session from the 2019 Fall Managed Care Forum. If you participated in the live session, you are not eligible for continuing education credits from this archive.

This activity is valid from January 1, 2020 to January 1, 2021

Instructions for CME/CNE: Complete the pre-test, listen to the audio and view the slides, complete the post test, complete the evaluation form and hit submit. You will be asked to enter your name and email address on the pre-test, evaluation and post-test. If you close your internet browser without completing the post test, you will have ONE more opportunity to complete. A score of 70% must be achieved on the post test to receive continuing education credits. If you do not pass the post test after two attempts, you will not be eligible to try again. Once you complete the evaluation form and score 70% or higher on your post test, you will automatically be given your certificate.

To print or save your certificate, you will need to click on the “download” button and either print or save.

 

Audience: This activity is intended for healthcare professionals practicing in managed care environments.

This presentation is supported by educational grants from
AbbVie, Bristol Myers Squibb, and Sanofi Genzyme
and Regeneron Pharmaceuticals

Description:
Rheumatoid arthritis (RA) is a long-lasting autoimmune disorder that occurs when the immune system mistakenly attacks the body's own tissues. It typically results in warm, swollen, and painful joints, and pain and stiffness often worsen following rest. Most commonly, the wrist and hands are involved, with the same joints typically involved on both sides of the body. The disease may also affect other parts of the body, which results in a low red blood cell count, inflammation around the lungs, and inflammation around the heart. According to the American College of Rheumatology (ACR), it is estimated that over 1.3 million people suffer from RA in the United States.

Diagnosis is done through examination, including x-rays and ultrasounds, and blood testing for certain indications and to rule out other possible causes for the symptoms. There is no cure for RA, treatment focuses on controlling the disease and its symptoms. However, even with all of the currently available non-biologic and biologic therapies, only about 1/3 of patients treated for RA ever achieve clinical remission. The remaining patients can experience continuous disease progression and disability. In addition, many patients will have an inadequate response or can become intolerant to the widely used anti-TNF therapies. Fortunately, new and emerging treatment strategies may offer additional therapeutic options to address the unmet needs of these patients. Clinicians have recently been equipped with more treatment options, including janus kinase (JAK) inhibitors, and several more have just completed late stage clinical trials and are currently undergoing regulatory review.

Upon completion of this activity, participants will be able to:

  • Explore efficacy and safety profiles of current and emerging biologic therapies for the treatment of moderate-to-severe RA for achieving individualized treatment goals

  • Discuss the role of anti-citrullinated protein antibodies (ACPAs), among other RA biomarkers, as part of the pathophysiology of RA

  • Examine interleukin-6 inhibition as a treat-to-target strategy in patients with moderate-to-severe RA

  • Explore the efficacy and safety data of new and emerging JAK inhibitors for the treatment of moderate-to-severe rheumatoid arthritis (RA) for achieving individualized treatment goals

  • Assess the managed care considerations of biomarkers and biologic therapies in the management of RA and the effect they have on the current moderate-to-severe RA management paradigm

  • Examine strategies to monitor and manage adverse events associated with current and emerging biologic therapies for the treatment of patients with moderate-to-severe RA in order to maximize tolerability and adherence to therapeutic regimens
     

Faculty: Vibeke Strand MD, MACR, FACP
Adjunct Clinical Professor
Division of Immunology/Rheumatology
Stanford University

Disclosure:

Dr. Strand has served on an advisory board and as a consultant forAbbvie, Amgen Corporation, Asana, AstraZeneca, Bayer, BMS, Boehringer Ingelheim, Celgene, Celltrion, CORRONA, Crescendo / Myriad Genetics, EMD Serono, Eupraxia, Flexion, Genentech, Glenmark, GSK, Horizon, Inmedix, Janssen, Kezar, Kypha, Lilly, Merck, Novartis, Pfizer, Regeneron, Royalty, RRD, Samsung, Samumed, Sandoz, Sanofi, Selecta, Servier, Setpoint, SKK, UCB. Her presentation has been peer reviewed for any bias.
  Planning Committee:
Bill Williams, MD has no relevant financial relationships to disclose.
Jeremy Williams has no relevant financial relationships to disclose.
Will Williams has no relevant financial relationships to disclose.
Jacqueline Cole, RN, MS, CMCN has no relevant financial relationships to disclose.

NAMCP and/or the presenter has copyright or has received permissions for use of materials provided in this activity.

Accreditation & Designation
The National Association of Managed Care Physicians (NAMCP) is accredited by the Accreditation Council for Continuing Medical Education (ACCME) to provide continuing medical education for physicians.

NAMCP designates this enduring material for a maximum of 1 AMA PRA Category 1 creditsTM.

The American Association of Managed Care Nurses (AAMCN) is accredited as a provider of nursing continuing professional development by the American Nurses Credentialing Center’s Commission on Accreditation.

Nurses who complete this activity and achieve a passing score will receive 1 hour in continuing
nursing credit.

This activity has been approved by the American Board of Managed Care Nursing for 1.0 contact hour toward CMCN recertification requirements.

This presentation is supported by educational grants from
AbbVie, Bristol Myers Squibb, and Sanofi Genzyme
and Regeneron Pharmaceuticals

NAMCP and/or this website does not provide medical advice, diagnosis or treatment. NAMCP does not endorse or imply endorsement of the content on any linked website. This website is to be used as an informational resource. With any health related concern, consult with your physician or healthcare professional.

Click Here To Continue